CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...